CD33 and acute myeloid leukemia: In addition, JNJ-67571244—another CD3- and CD33-specific bsAb-based T-cell engager—has been included in a phase I clinical study (NCT03915379) to evaluate its safety and clinical activity in patients with R/R AML, as well as those with high-risk or very-high-risk myelodysplastic syndrome [299].